REG4

Summary

REG4 (regenerating family member 4, HGNC:22977) is a protein-coding gene on chromosome 1p12, encoding Regenerating islet-derived protein 4 (Q9BYZ8). Calcium-independent lectin displaying mannose-binding specificity and able to maintain carbohydrate recognition activity in an acidic environment.

Enables heparin binding activity and mannan binding activity. Predicted to act upstream of or within response to bacterium. Located in cytoplasm.

Source: NCBI Gene 83998 — RefSeq curated summary.

At a glance

• GWAS associations: 1
• Clinical variants (ClinVar): 34 total
• MANE Select transcript: NM_032044

Identifiers

Gene identifiers

Field	Value
HGNC ID	HGNC:22977
Approved symbol	REG4
Name	regenerating family member 4
Location	1p12
Locus type	gene with protein product
Status	Approved
Aliases	REG-IV, RELP, GISP
Ensembl gene	ENSG00000134193
Ensembl biotype	protein_coding
OMIM	609846
Entrez	83998

Gene structure

Transcript identifiers

Ensembl transcripts: 5 — 5 protein_coding

ENST00000256585, ENST00000354219, ENST00000369401, ENST00000530654, ENST00000871091

RefSeq mRNA: 3 — MANE Select: NM_032044 NM_001159352, NM_001159353, NM_032044

CCDS: CCDS53354, CCDS906

Canonical transcript exons

ENST00000256585 — 6 exons

Exon	Start	End
ENSE00000913356	119803068	119803165
ENSE00000913357	119799725	119799862
ENSE00000913358	119798497	119798602
ENSE00001022832	119808703	119808863
ENSE00001353646	119794017	119794685
ENSE00001883368	119811409	119811460

Expression profiles

Bgee: expression breadth ubiquitous, 115 present calls, max score 99.92.

FANTOM5 (CAGE): breadth tissue_specific, TPM avg 0.7725 / max 435.7278, expressed in 25 samples.

FANTOM5 promoters (1 alternative TSS)

Promoter ID	TPM avg	Samples expressed
14092	0.7725	25

Top tissues by expression

231 total, by Bgee expression score (0-100, higher = more expressed):

Tissue	Anatomy ID	Expression score	Quality
ileal mucosa	UBERON:0000331	99.92	gold quality
duodenum	UBERON:0002114	98.41	gold quality
jejunal mucosa	UBERON:0000399	98.22	gold quality
body of pancreas	UBERON:0001150	96.39	gold quality
small intestine Peyer’s patch	UBERON:0003454	94.85	gold quality
mucosa of sigmoid colon	UBERON:0004993	94.33	gold quality
rectum	UBERON:0001052	93.42	gold quality
small intestine	UBERON:0002108	92.99	gold quality
colonic mucosa	UBERON:0000317	91.37	gold quality
pancreatic ductal cell	CL:0002079	90.85	gold quality
vermiform appendix	UBERON:0001154	90.08	gold quality
pancreas	UBERON:0001264	86.76	gold quality
male germ line stem cell (sensu Vertebrata) in testis	CL:0000089 ∩ UBERON:0000473	83.94	gold quality
mucosa of transverse colon	UBERON:0004991	83.49	gold quality
caecum	UBERON:0001153	80.70	gold quality
jejunum	UBERON:0002115	78.61	gold quality
intestine	UBERON:0000160	73.27	gold quality
tibialis anterior	UBERON:0001385	71.98	silver quality
transverse colon	UBERON:0001157	71.91	gold quality
islet of Langerhans	UBERON:0000006	71.40	gold quality
cardiac muscle of right atrium	UBERON:0003379	70.97	gold quality
epithelial cell of pancreas	CL:0000083	70.84	silver quality
left ventricle myocardium	UBERON:0006566	70.77	gold quality
large intestine	UBERON:0000059	66.42	gold quality
myocardium	UBERON:0002349	66.05	gold quality
kidney epithelium	UBERON:0004819	65.98	gold quality
upper arm skin	UBERON:0004263	65.39	gold quality
smooth muscle tissue	UBERON:0001135	65.34	gold quality
colon	UBERON:0001155	65.17	gold quality
colonic epithelium	UBERON:0000397	64.34	gold quality

Single-cell (SCXA)

Detected in 6 experiment(s), a significant marker in 6.

Experiment	Marker?	Max mean expression
E-GEOD-125970	yes	17299.70
E-MTAB-8410	yes	2847.07
E-MTAB-8495	yes	1054.57
E-MTAB-9543	yes	870.31
E-CURD-84	yes	499.19
E-ANND-3	no	0.00

Regulation

Is transcription factor: no

Upstream regulators (CollecTRI, top): CDX2, GLI1, TSG101

miRNA regulators (miRDB)

30 targeting REG4, top 30 by miRDB confidence (max_score; target_count = how many genes the miRNA targets in total — lower means more specific):

miRNA	Max score	Avg score	miRNA target_count
HSA-MIR-3692-3P	99.98	70.27	2139
HSA-MIR-6888-3P	99.97	65.95	1170
HSA-MIR-3682-5P	99.93	67.97	1163
HSA-MIR-4320	99.75	65.80	793
HSA-MIR-4470	99.66	69.35	1767
HSA-MIR-4762-5P	99.57	68.54	1424
HSA-MIR-4318	99.38	66.94	1505
HSA-MIR-4505	99.27	67.81	2678
HSA-MIR-5787	99.22	67.86	2628
HSA-MIR-6734-3P	99.15	66.27	1627
HSA-MIR-3926	98.95	69.26	1438
HSA-MIR-4724-5P	98.87	67.75	1324
HSA-MIR-4755-3P	98.77	65.59	1915
HSA-MIR-6794-3P	98.76	66.99	894
HSA-MIR-9500	98.62	66.54	1845
HSA-MIR-7114-5P	98.51	67.87	1349
HSA-MIR-548S	98.50	67.17	1213
HSA-MIR-4722-5P	98.46	66.34	1611
HSA-MIR-6826-3P	98.19	66.32	1153
HSA-MIR-4664-5P	98.17	65.07	1020
HSA-MIR-4468	98.01	66.85	1187
HSA-MIR-6511B-5P	97.98	65.64	823
HSA-MIR-6811-5P	97.98	64.96	848
HSA-MIR-4433A-3P	97.75	62.82	1435
HSA-MIR-4676-5P	97.54	65.29	715
HSA-MIR-575	97.54	65.18	718
HSA-MIR-342-5P	97.25	64.10	817
HSA-MIR-2276-5P	96.27	65.85	937
HSA-MIR-4758-5P	94.82	67.06	499
HSA-MIR-1238-5P	94.82	67.52	493

Literature-anchored findings (GeneRIF, showing 40)

• Results suggest that RELP might be involved in inflammatory and metaplastic responses of the gastrointestinal epithelium. (PMID:12819006)
• overexpression of Reg IV may be an early event in colorectal carcinogenesis. (PMID:14550954)
• Increased expression of Reg IV is associated wirh hormone refractory metastatic prostate cancer (PMID:15788672)
• RELP serves as a marker for appendiceal mucinous cystadenomas and pseudomyxoma peritonei and may contribute to the pathogenesis of these disorders. (PMID:16323007)
• Reg IV is a potent activator of the EGF receptor/Akt/AP-1 signaling pathway in colorectal carcinoma (PMID:16401477)
• Overexpression of REG4 is associated with pancreatic cancer (PMID:16918991)
• serum Reg IV concentration may predict metastatic recurrence of colorectal cancer in the liver.Reg IV protein expression induced by growth factors may function as a growth-promoting and/or an antiapoptotic factor in the peritumoral mucosa of CRC. (PMID:18187959)
• RegIV expression was markedly higher in gastric cancer patients with peritoneal metastases compared to those without; level of RegIV mRNA in gastric cancer patients was related to the extent of wall penetration (PMID:18505053)
• Reg IV staining can aid in diagnosis of gastrointestinal signet ring cell carcinoma. (PMID:18580680)
• These results suggest that Reg IV expression is an independent prognostic indicator of relapse after radical prostatectomy. (PMID:18754868)
• Reg IV might accelerate cell growth and disease progression of adenoid cystic carcinomas . (PMID:19076683)
• among major urologic cancers, Reg IV is expressed frequently in prostate cancer, and that serum Reg IV represents a novel biomarker for prostate cancer (PMID:19082448)
• REG4 is involved in the ‘intestinal’ pathway of carcinogenesis in intraductal papillary mucinous neoplasms of the pancreas (PMID:19136934)
• Reg IV might accelerate peritoneal metastasis in gastric cancer. Reg IV in lavage fluids might be a good marker for peritoneal metastasis (PMID:19143768)
• Expression of REG Ialpha but not REG IV was an independent predictor of poor outcome in patients with gastric cancer. (PMID:19329938)
• Data demonstrated in vitro and in vivo that REG4 protein overexpression was associated with an unfavorable response to preoperative chemoradiotherapy. (PMID:19546835)
• Reg IV is involved in gallbladder carcinoma carcinogenesis through intestinal metaplasia and is associated with relatively favorable prognosis in patients after surgery (PMID:19716164)
• Reg IV expression experienced up-regulation in gastric intestinal metaplasia and adenoma and then down-regulation with malignant transformation of gastric epithelial cells. (PMID:19740514)
• REG4 is expressed in pancreatic cancer, and serum levels of REG4 offer a useful indicator for distinguishing between patients with pancreatic cancer and healthy subjects (PMID:19789838)
• reg4 is amplified in the early stages of pancreatic cancer development (PMID:19834624)
• Reg IV as an important modulator of gastrointestinal cell susceptibility to irradiation; hence, it is a potential target for adjunctive treatments for human colorectal cancer and other gastrointestinal malignancies. (PMID:19900450)
• Local Reg IV expression may be influenced by the growth factors basic fibroblast growth factor and somatotropin and dtheri receptors (PMID:19924642)
• REG4 may play an important role in the development and progression of colorectal cancer, as well as in intestinal morphogenesis and epithelium restitution (PMID:20126989)
• REG IV overexpression may be an early event in colorectal carcinoma carcinogenesis. (PMID:20183800)
• RegIV is expressed in the gastrointestinal tract and in digestive tract neuroendocrine tumor (PMID:20349522)
• RegIV enhances LoVo cell migration and invasion, and its CRD domain is critical for these effects. (PMID:20417867)
• The solution structure of hRegIV-P91S was determined, showing that it adopts a typical fold of C-type lectin. Based on the chemical shift perturbations of amide resonances, two calcium-independent mannan-binding sites were proposed (PMID:20692269)
• REG4 may be a prognostic indicator and a better serum marker than carcinoembryonic antigen and carbohydrate antigen 19-9 for early diagnosis of gastric cancer. (PMID:21419474)
• Knockdown of Reg IV impacted the ability of insulin and EGF to stimulate downstream tyrosine phosphorylation. (PMID:21445968)
• Overexpression of REGIV mRNA is assessed with peritoneal recurrence in gastric adenocarcinoma. (PMID:21780125)
• REG4, BIRC5 and NEIL2 genes might have a role in the sensitivity of cancer patients to radiotherapy (PMID:22199273)
• TGF-beta signalling reduces the expression of ALDH1 and REG4, and the size of the ALDH1+ cell population. (PMID:22430847)
• Suggest that Reg IV might accelerate disease progression and act as a candidate prognostic marker for gliomas. (PMID:22713481)
• REG4 promotes not only growth but also in vitro invasiveness of pancreatic cancer cells by upregulating MMP-7 and MMP-9. (PMID:22957785)
• RegIV may play an important role in the intrinsic resistance of gastric cancer cells to 5-FU. (PMID:23010741)
• CDX2 protein directly regulates Reg IV expression in gastric cancer (PMID:23133598)
• The Reg IV may be involved in the finetuning of functions exerted by the neuroendocrine cells in the GI-tract. (PMID:23499801)
• Immunohistochemistry against known cell-type markers on serial sections has localised the expression of REGs to metaplastic Paneth cells (REG1A, REG1B and REG3A) and enteroendocrine cells (REG4), with a marked expansion of expression during inflammation. (PMID:23519454)
• REG4 expression is common in mucinous borderline ovarian tumors of the intestinal type as it is absent in the endocervical-like form tumors. (PMID:23958547)
• the stemness properties of control mammospheres and RegIV knockdown mammospheres were compared by tumourigenicity assay in vivo and plate colony formation assay in vitro. (PMID:24064664)

Cross-species orthologs

3 orthologs

Organism	Symbol	Gene ID
mus_musculus	Reg4	ENSMUSG00000027876
rattus_norvegicus	Reg4	ENSRNOG00000019046
caenorhabditis_elegans		WBGENE00019914

Paralogs (5): REG1A (ENSG00000115386), REG3G (ENSG00000143954), REG3A (ENSG00000172016), REG1B (ENSG00000172023), CLEC19A (ENSG00000261210)

Protein

Protein identifiers

Regenerating islet-derived protein 4 — Q9BYZ8 (reviewed: Q9BYZ8)

Alternative names: Gastrointestinal secretory protein, REG-like protein, Regenerating islet-derived protein IV

All UniProt accessions (2): E9PNV6, Q9BYZ8

UniProt curated annotations — full annotation on UniProt →

Function. Calcium-independent lectin displaying mannose-binding specificity and able to maintain carbohydrate recognition activity in an acidic environment. May be involved in inflammatory and metaplastic responses of the gastrointestinal epithelium.

Subcellular location. Secreted.

Tissue specificity. Highly expressed in the gastrointestinal tract including the duodenum, jejunum, ileum, ileocecum, appendix, descending colon, pancreas and small intestine. Weakly expressed in normal colon and stomach. Strongly expressed in most colorectal tumors than in normal colon. Preferentially expressed in mucinous tumors and in some cases neuro-endocrine tumors. Expressed in mucus-secreting cells and enterocyte-like cells. In small intestine expressed at the basal perinuclear zone of goblet cells.

Induction. Up-regulated by mucosal injury from active Crohn’s disease or ulcerative colitis. Up-regulated in colorectal tumors. Up-regulated in epithelial cells at regenerating margins of peptic ulcers in the stomach and duodenum.

Isoforms (2)

UniProt ID	Names	Canonical?
Q9BYZ8-1	1	yes
Q9BYZ8-2	2

RefSeq proteins (3): NP_001152824, NP_001152825, NP_114433* (*=MANE)

Domains & families (InterPro)

ID	Name	Type
IPR001304	C-type_lectin-like	Domain
IPR016186	C-type_lectin-like/link_sf	Homologous_superfamily
IPR016187	CTDL_fold	Homologous_superfamily
IPR018378	C-type_lectin_CS	Conserved_site
IPR050111	C-type_lectin/snaclec_domain	Family

Pfam: PF00059

UniProt features (21 total): strand 7, disulfide bond 3, splice variant 2, helix 2, binding site 2, signal peptide 1, chain 1, sequence variant 1, domain 1, glycosylation site 1

Structure

Experimental structures (PDB)

1 structures.

PDB	Method	Resolution (Å)
2KV3	SOLUTION NMR

Predicted structure (AlphaFold)

Model	pLDDT	Fraction very-high
AF-Q9BYZ8-F1	89.17	0.77

Functional residue map

Curated UniProt residues grouped by drug-discovery relevance — catalytic, ligand-binding, modification, and mutation-validated positions. Source: UniProtKB sequence features.

Ligand- & substrate-binding residues (2): 98–103; 135–137

Disulfide bonds (3): 30–41, 58–154, 129–146

Glycosylation sites (1): 50

Function

Pathways and Gene Ontology

Reactome pathways

0 pathways

MSigDB gene sets: 87 (showing top): WATANABE_COLON_CANCER_MSI_VS_MSS_UP, GATA6_01, GOMF_GLYCOSAMINOGLYCAN_BINDING, chr1p12, GATA1_02, GOMF_HEPARIN_BINDING, GOMF_SULFUR_COMPOUND_BINDING, GOBP_RESPONSE_TO_BACTERIUM, GOMF_POLYSACCHARIDE_BINDING, MARTENS_TRETINOIN_RESPONSE_UP, VECCHI_GASTRIC_CANCER_ADVANCED_VS_EARLY_DN, FEVR_CTNNB1_TARGETS_DN, ANDERSEN_CHOLANGIOCARCINOMA_CLASS2, CEBPE_TARGET_GENES, DLX2_TARGET_GENES

GO Biological Process (1): response to bacterium (GO:0009617)

GO Molecular Function (4): heparin binding (GO:0008201), signaling receptor activity (GO:0038023), mannan binding (GO:2001065), carbohydrate binding (GO:0030246)

GO Cellular Component (2): extracellular region (GO:0005576), cytoplasm (GO:0005737)

GO top-level categories

Rollup of top GO terms by namespace:

Category	Terms
cellular anatomical structure	2
response to other organism	1
glycosaminoglycan binding	1
sulfur compound binding	1
molecular transducer activity	1
polysaccharide binding	1
binding	1
intracellular anatomical structure	1

Protein interactions and networks

STRING

730 interactions, top by confidence (×1000):

Protein A	Protein B	Partner UniProt	Score
REG4	TFF3	Q07654	654
REG4	GPR37	O15354	629
REG4	KRT20	P35900	587
REG4	TFF2	Q03403	540
REG4	SPINK4	O60575	532
REG4	LGR5	O75473	530
REG4	MS4A12	Q9NXJ0	498
REG4	EXTL3	O43909	485
REG4	OLFM4	Q6UX06	483
REG4	CLDN18	P56856	477
REG4	MUC2	Q02817	456
REG4	ZG16	O60844	453
REG4	ZC3H12A	Q5D1E8	445
REG4	AGR2	O95994	439
REG4	SPINK8	P0C7L1	426

IntAct

4 interactions, top by confidence:

A	B	Type	Score
REG4	ATE1	psi-mi:“MI:0914”(association)	0.530

BioGRID (14): ATE1 (Affinity Capture-MS), HTRA1 (Affinity Capture-MS), UBAC1 (Affinity Capture-MS), KLHL26 (Affinity Capture-MS), SIRT3 (Affinity Capture-MS), RNF123 (Affinity Capture-MS), SIRT3 (Affinity Capture-MS), RNF123 (Affinity Capture-MS), ATE1 (Affinity Capture-MS), HTRA1 (Affinity Capture-MS), PITRM1 (Affinity Capture-MS), KLHL26 (Affinity Capture-MS), UBAC1 (Affinity Capture-MS), KLHL22 (Affinity Capture-MS)

ESM2 similar proteins: A1XXJ9, A7X3X0, A7X3X3, A7X3X8, A7X3Y2, B5U6Y6, D2YVH7, D2YVJ8, D2YVK5, D8VNS6, I7ICN3, O09037, O09049, O93426, O93427, P05451, P0DM38, P10758, P23132, P23807, P25031, P35230, P35231, P42854, P43137, P48304, P81112, P81114, Q06141, Q08731, Q09GJ8, Q09GK0, Q56EB0, Q5FZI6, Q68AX7, Q6TPG9, Q6UW15, Q6X5S0, Q6X5S1, Q6X5S4

Diamond homologs: A1XXJ9, A3FM55, A7X3W1, A7X3W6, A7X3X0, A7X3X3, A7X3X8, A7X3Y2, A7X3Y6, A7X3Z0, A7X3Z4, A7X3Z7, A7X401, A7X406, A7X409, A7X413, B0VXV0, B0VXV1, B5U6Y6, C6JUN9, D1MGU0, D2YVH7, D2YVI2, D2YVJ6, D2YVJ8, D2YVK1, D2YVK5, D2YW40, D8VNS6, I7ICN3, J3S3U6, J3SBP0, O93427, P05451, P07439, P0DL30, P0DM36, P0DM38, P0DM39, P0DM53

SIGNOR signaling

0 interactions.

Disease & clinical

Clinical variants and AI predictions

ClinVar

34 variants total. Per-class counts are floors (≥ shown; pagination cap):

Classification	Count (floor)
Pathogenic	0
Likely pathogenic	0
Uncertain significance	27
Likely benign	2
Benign	1

Top pathogenic / likely-pathogenic (0)

SpliceAI

889 predictions. Top by Δscore:

Variant	Effect	Δscore
1:119794683:AGT:A	acceptor_gain	0.9900
1:119794683:AGTC:A	acceptor_loss	0.9900
1:119794685:TCT:T	acceptor_loss	0.9900
1:119794686:C:CC	acceptor_gain	0.9900
1:119794687:T:A	acceptor_loss	0.9900
1:119803062:TCTTA:T	donor_loss	0.9900
1:119803063:CTTA:C	donor_loss	0.9900
1:119803064:TTACC:T	donor_loss	0.9900
1:119803065:TACCT:T	donor_loss	0.9900
1:119803067:C:CA	donor_loss	0.9900
1:119803161:GATAT:G	acceptor_gain	0.9900
1:119803162:ATATC:A	acceptor_loss	0.9900
1:119803163:TAT:T	acceptor_gain	0.9900
1:119803163:TATC:T	acceptor_loss	0.9900
1:119803164:ATC:A	acceptor_loss	0.9900
1:119803165:TCTGC:T	acceptor_loss	0.9900
1:119803166:C:CC	acceptor_gain	0.9900
1:119803167:T:A	acceptor_loss	0.9900
1:119803172:A:C	acceptor_gain	0.9900
1:119811403:GATTA:G	donor_loss	0.9900
1:119811404:ATTAC:A	donor_loss	0.9900
1:119811406:TA:T	donor_loss	0.9900
1:119811408:C:CA	donor_loss	0.9900
1:119811440:G:A	donor_gain	0.9900
1:119794681:AAAGT:A	acceptor_gain	0.9800
1:119794682:AAGT:A	acceptor_gain	0.9800
1:119794684:GT:G	acceptor_gain	0.9800
1:119803162:ATAT:A	acceptor_gain	0.9700
1:119803164:AT:A	acceptor_gain	0.9700
1:119803171:C:CT	acceptor_gain	0.9700

AlphaMissense

1049 scored. Top likely-pathogenic:

Variant	Protein change	am_pathogenicity
1:119798585:C:A	W107C	0.993
1:119798585:C:G	W107C	0.993
1:119794634:C:G	C154S	0.991
1:119794635:A:T	C154S	0.991
1:119799855:C:G	C58S	0.991
1:119799856:A:T	C58S	0.991
1:119803080:C:A	W51C	0.991
1:119803080:C:G	W51C	0.991
1:119794639:G:C	F152L	0.990
1:119794639:G:T	F152L	0.990
1:119794641:A:G	F152L	0.990
1:119794672:C:A	W141C	0.990
1:119794672:C:G	W141C	0.990
1:119803073:C:G	A54P	0.990
1:119799749:C:A	W93C	0.989
1:119799749:C:G	W93C	0.989
1:119798591:C:A	W105C	0.987
1:119798591:C:G	W105C	0.987
1:119799854:A:C	C58W	0.983
1:119803131:C:A	W34C	0.982
1:119803131:C:G	W34C	0.982
1:119798520:C:G	C129S	0.980
1:119798521:A:T	C129S	0.980
1:119798587:A:G	W107R	0.979
1:119798587:A:T	W107R	0.979
1:119799856:A:G	C58R	0.979
1:119794658:C:G	C146S	0.977
1:119794659:A:T	C146S	0.977
1:119799855:C:T	C58Y	0.977
1:119803111:C:G	C41S	0.977

dbSNP variants (sampled 300 via entrez): RS1000000493 (1:119800862 G>A), RS1000019976 (1:119804673 T>C), RS1000079425 (1:119799185 CCA>C), RS1000117501 (1:119801930 G>A,C), RS1000161888 (1:119797781 G>A), RS1000587759 (1:119795032 C>A), RS1000640220 (1:119794850 T>C), RS1000669861 (1:119809341 T>C), RS1000947103 (1:119795133 A>C,G), RS1001198166 (1:119799563 A>G), RS1001221056 (1:119810032 T>C), RS1001274689 (1:119795337 T>C,G), RS1001314148 (1:119799831 T>C), RS1001429235 (1:119794349 T>C), RS1001826166 (1:119805052 C>A)

Disease associations

OMIM: gene MIM:609846 | disease phenotypes:

GenCC curated gene-disease

Mondo (0):

Orphanet (0):

HPO phenotypes

0 total (0 of 0 shown, HPO-id order):

GWAS associations

1 associations (top):

Study	Trait	p-value
GCST006585_2242	Blood protein levels	2.000000e-09

Drugs & pharmacology

Drug and pharmacology data

Is drug target: no

PharmGKB: 1 entry (VIP=true, CPIC=false)

CTD chemical–gene interactions

16 total (human), top 16 by PubMed support.

Chemical	Actions (top 5)	PubMed papers
propionaldehyde	decreases expression	1
terbufos	increases methylation	1
perfluorooctanoic acid	increases expression	1
CGP 52608	increases reaction, affects binding	1
perfluoro-n-nonanoic acid	increases expression	1
entinostat	increases expression	1
perfluorohexanesulfonic acid	increases expression	1
NSC 689534	affects binding, decreases expression	1
(+)-JQ1 compound	decreases expression	1
Arsenic	affects methylation	1
Benzo(a)pyrene	increases methylation	1
Copper	affects binding, decreases expression	1
Fonofos	increases methylation	1
Fluorouracil	decreases response to substance	1
Hydrogen Peroxide	affects expression	1
Parathion	increases methylation	1

Clinical trials (associated diseases)

0 trials via MONDO — disease-level, not drug-specific.